Innovation, influence and business in America's medical cities.

Sponge-safety company ClearCount Medical Solutions has hired a new chief financial officer.In his new role, David Haffner will oversee the day-to-day financial operations of the company and will be responsible for its financial strategy, according to a statement from Pittsburgh-based [...]

ThermalTherapeutic Systems Inc. has received clearance from the U.S. Food and Drug Administration to begin selling its flagship portable perfusion device, which is used to pump fluid into the abdomen or chest cavity of patients suffering from hyperthermia.Obtaining FDA clearance of the Veratherm Portable Hyperthermic Perfusion System is a “critical step,” for the company, which [...]

Generic drugmaker Mylan Pharmaceuticals Inc. has received FDA approval to begin shipping a generic version of a drug that treats gallstones.Ursodial USP is the generic version of Watson Pharmaceuticals’ Actigall capsules. A number of other drugmakers sell Ursodial capsules, including Lannett Company and Teva Pharmaceuticals.Ursodia USP is a bile acid that naturally occurs in the [...]

ALung Technologies Inc. has raised $3.3 million in equity as part of an intended $10 million offering. The company is developing a respiratory-assistance system it calls the Hemolung, which delivers oxygen directly into the blood using a catheter into the femoral or jugular vein.

Lipella Pharmaceuticals has big plans for the rest of the year, including raising its first venture funding and completing clinical trials for its drug that treats two common bladder conditions.

ClearCount Medical Solutions has received clearance from the FDA for its SmartWand-DTX sponge-counting system, a smaller, lower-cost, more-portable alternative to its sponge-detection system already on the market.

Louisville-based Chrysalis Ventures led the round, accompanied by Health Evolution Partners and Foundation’s management team. The company plans to use the funding to further invest in its technology and “expand its geographic footprint.”

Cohera’s lead product is called TissuGlu and is designed to minimize fluid accumulation and other problems associated with abdominoplasty, or “tummy-tuck” surgeries.

The Pittsburgh-based company is developing what it calls the cardioARM device, a robotic method to treat heart arrhythmia using a single-port, epicardial procedure.

Thar Pharmaceuticals Inc. has raised $1.2 million in debt financing to commercialize drugs based on supercritical fluid technologies, according to a regulatory filing.